文献速递产科

分娩期间外源性缩宫素给药与孤独症谱系障碍

Exogenous oxytocin administration during labor and autism spectrum disorder.
PubMed 文献 · Am J Obstet Gynecol MFM · 2023-05-06

这项基于人群的回顾性队列研究纳入加拿大不列颠哥伦比亚省2000年4月1日至2014年12月31日出生的414,336名儿童和以色列索罗卡大学医学中心2011年1月1日至2019年12月31日出生的82,892名儿童,比较产时缩宫素暴露与孤独症谱系障碍诊断的关联。在以色列队列中,缩宫素加强宫缩者调整后风险比为1.51(95%CI 1.20-1.90),其他方式引产且未加强宫缩者为2.18(95%CI 1.32-3.57),但缩宫素引产无显著关联;加拿大队列无统计学显著的调整后风险比。结论支持缩宫素引产不增加儿童孤独症谱系障碍风险,既往阳性关联可能受引产指征混杂。

要点

  • 缩宫素引产与儿童孤独症谱系障碍无显著关联。
  • 以色列队列中缩宫素加强宫缩的调整后HR为1.51(95%CI 1.20-1.90)。
  • 其他方式引产且未加强宫缩的调整后HR为2.18(95%CI 1.32-3.57)。

核心结论

  • 本研究支持缩宫素引产不增加儿童孤独症谱系障碍风险。
  • 两国临床实践差异的国际比较提示,既往报告显著关联的研究很可能被引产潜在指征混杂。

研究设计与样本

  • 基于人群的回顾性队列研究,比较加拿大不列颠哥伦比亚省2000年4月1日至2014年12月31日出生的414,336名儿童与以色列索罗卡大学医学中心2011年1月1日至2019年12月31日出生的82,892名儿童。
  • 检查9种不同的暴露组,使用Cox比例风险模型估计孤独症谱系障碍的粗风险比和调整后风险比。
  • 在健康无并发症分娩队列和仅因过期妊娠引产组中进行敏感性分析,并按婴儿性别分层。

主要发现

  • 不列颠哥伦比亚省队列中,414,336次分娩里170,013次(41.0%)未引产或加强宫缩,107,543次(26.0%)暴露于缩宫素,136,780次(33.0%)引产或加强宫缩但未暴露于缩宫素。
  • 以色列队列中,82,892次分娩里51,790次(62.5%)未引产或加强宫缩,28,852次(34.8%)暴露于缩宫素,2250次(2.7%)引产或加强宫缩但未暴露于缩宫素。
  • 以色列队列主分析中,缩宫素加强宫缩的调整后风险比为1.51(95%CI 1.20-1.90),其他方式引产且未加强宫缩为2.18(95%CI 1.32-3.57),缩宫素引产无显著关联。
  • 加拿大队列无统计学显著的调整后风险比。
  • 完全调整模型中未观察到显著的性别差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oxytocin is a neuropeptide hormone that plays a key role in social behavior, stress regulation, and mental health. Synthetic oxytocin administration is a common obstetrical practice, and importantly, previous research has suggested that intrapartum exposure may increase the risk of neurodevelopmental disorders, such as autism spectrum disorder. OBJECTIVE: This study aimed to examine the association between synthetic oxytocin exposure during labor and autism spectrum disorder diagnosis in the child. STUDY DESIGN: This population-based retrospective cohort study compared 2 cohorts of children: (1) all children born in British Columbia, Canada between April 1, 2000 and December 31, 2014 (n=414,336 births), and (2) all children delivered at Soroka University Medical Center in Be'er-Sheva, Israel between January 1, 2011 and December 31, 2019 (n=82,892 births). Nine different exposure groups were examined. Cox proportional hazards models were used to estimate crude and adjusted hazard ratios of autism spectrum disorder in both cohorts on the basis of induction and/or augmentation exposure status. To further control for confounding by indication, we conducted sensitivity analyses among a cohort of healthy, uncomplicated deliveries and among a group that was induced only for postdates. In addition, we stratified our analyses by infant sex to assess for potential sex differences. RESULTS: In the British Columbia cohort, 170,013 of 414,336 deliveries (41.0%) were not induced or augmented, 107,543 (26.0%) were exposed to oxytocin, and 136,780 (33.0%) were induced or augmented but not exposed to oxytocin. In the Israel cohort, 51,790 of 82,892 deliveries (62.5%) were not induced or augmented, 28,852 (34.8%) were exposed to oxytocin, and 2250 (2.7%) were induced or augmented but not exposed to oxytocin. On adjusting for covariates in the main analysis, significant associations were observed in the Israel cohort, including adjusted hazard ratios of 1.51 (95% confidence interval, 1.20-1.90) for oxytocin-augmented births and 2.18 (95% confidence interval, 1.32-3.57) for those induced by means other than oxytocin and not augmented. However, oxytocin induction was not significantly associated with autism spectrum disorder in the Israel cohort. In the Canadian cohort, there were no statistically significant adjusted hazard ratios. Further, no significant sex differences were observed in the fully adjusted models. CONCLUSION: This study supports that induction of labor through oxytocin administration does not increase the risk of autism spectrum disorder in the child. Our international comparison of 2 countries with differences in clinical practice regarding oxytocin administration for induction and/or augmentation suggests that previous studies reporting a significant association were likely confounded by the underlying indication for the induction.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Karim JL, Solomon S, Abreu do Valle H, et al. Exogenous oxytocin administration during labor and autism spectrum disorder. Am J Obstet Gynecol MFM. 2023. PMID: 37156463. doi:10.1016/j.ajogmf.2023.101010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。